Home › Compare › GMELF vs MRK

GMELF vs MRK: Dividend Comparison 2026

GMELF yields 81632.65% · MRK yields 3.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GMELF wins by $6.371281177285151e+25M in total portfolio value
10 years
GMELF
GMELF
● Live price
81632.65%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$6.371281177285151e+25M
Annual income
$63,559,648,248,658,050,000,000,000,000,000.00
Full GMELF calculator →
MRK
Merck & Co. Inc.
● Live price
3.25%
Share price
$94.80
Annual div
$3.08
5Y div CAGR
8.2%
Payout ratio
42%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.7K
Annual income
$950.29
Full MRK calculator →

Portfolio growth — GMELF vs MRK

📍 GMELF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGMELFMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GMELF + MRK cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
GMELF pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GMELF
Annual income on $10K today (after 15% tax)
$6,938,775.51/yr
After 10yr DRIP, annual income (after tax)
$54,025,701,011,359,335,000,000,000,000,000.00/yr
MRK
Annual income on $10K today (after 15% tax)
$276.16/yr
After 10yr DRIP, annual income (after tax)
$807.75/yr
At 15% tax rate, GMELF beats the other by $54,025,701,011,359,335,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GMELF + MRK for your $10,000?

GMELF: 50%MRK: 50%
100% MRK50/50100% GMELF
Portfolio after 10yr
$3.1856405886425756e+25M
Annual income
$31,779,824,124,329,023,000,000,000,000,000.00/yr
Blended yield
99.76%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

GMELF
No analyst data
Altman Z
-3.3
Piotroski
3/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+35.6% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GMELF buys
0
MRK buys
0
No recent congressional trades found for GMELF or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGMELFMRK
Forward yield81632.65% ✓3.25%
Annual dividend / share$2.00$3.08 ✓
Payout ratio50%42% ✓
1-year div growth0%5.5% ✓
5-year div CAGR0%8.2% ✓
Portfolio after 10y$6.371281177285151e+25M$30.7K ✓
Annual income after 10y$63,559,648,248,658,050,000,000,000,000,000.00 ✓$950.29
Total dividends collected$6.370277064525336e+25M ✓$6.1K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: GMELF vs MRK ($10,000, DRIP)

YearGMELF PortfolioGMELF Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$8,173,965$8,163,265.31$11,192$351.54+$8.16M → GMELF
2$6,244,844,030$6,236,097,887.56$12,524$392.70+$6244.83M → GMELF
3$4,459,325,761,245$4,452,643,778,132.29$14,015$438.65+$4459325.75M → GMELF
4$2,976,312,826,539,111$2,971,541,347,974,579.00$15,682$489.96+$2976312826.52M → GMELF
5$1,856,747,760,783,437,000$1,853,563,106,059,039,700.00$17,547$547.23+$1856747760783.42M → GMELF
6$1,082,668,754,574,110,900,000$1,080,682,034,470,072,500,000.00$19,632$611.16+$1082668754574110.88M → GMELF
7$590,079,194,816,020,250,000,000$588,920,739,248,626,000,000,000.00$21,963$682.53+$590079194816020224.00M → GMELF
8$300,608,255,157,346,100,000,000,000$299,976,870,418,892,980,000,000,000.00$24,571$762.18+$300608255157346107392.00M → GMELF
9$143,143,480,554,639,230,000,000,000,000$142,821,829,721,620,860,000,000,000,000.00$27,486$851.08+$1.4314348055463923e+23M → GMELF
10$63,712,811,772,851,510,000,000,000,000,000$63,559,648,248,658,050,000,000,000,000,000.00$30,745$950.29+$6.371281177285151e+25M → GMELF

GMELF vs MRK: Complete Analysis 2026

GMELF — Stock

GOME Retail Holdings Limited, together with its subsidiaries, engages in the retail of electrical appliances, consumer electronic products, and general merchandise in the People's Republic of China. The company also sells its products online through self-operated and platform models. In addition, it is involved in the provision of logistics and procurement, storage and delivery, IT development, and business management services; retailing of mobile phones and accessories; and property holding activities. As of December 31, 2021, it operated 4,195 stores in 1,439 cities. The company was formerly known as GOME Electrical Appliances Holding Limited and changed its name to GOME Retail Holdings Limited in 2017. GOME Retail Holdings Limited was founded in 1987 and is headquartered in Central, Hong Kong.

Full GMELF Calculator →

MRK — Healthcare

Merck is a Dividend Aristocrat with 14+ consecutive years of increases. Keytruda (pembrolizumab) is the world's best-selling cancer drug and drives exceptional cash generation. The company's oncology and vaccines pipeline provides long-term growth visibility beyond the Keytruda patent cliff in the 2030s.

Full MRK Calculator →
📬

Get this GMELF vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GMELF vs SCHDGMELF vs JEPIGMELF vs OGMELF vs KOGMELF vs MAINGMELF vs JNJGMELF vs ABBVGMELF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.